Journey Medical (DERM) Income towards Parent Company (2020 - 2026)

Journey Medical (DERM) has reported Income towards Parent Company for 7 consecutive years, with -$312000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Income towards Parent Company rose 91.78% year-over-year to -$312000.0; the trailing twelve-month figure through Jun 2026 stood at -$3.7 million (up 57.87% YoY), and the FY2025 full-year result was -$9.0 million, up 38.77% from the prior year.
• Income towards Parent Company advanced to -$312000.0 in Q2 2026 per DERM's latest filing, from -$2.2 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $16.8 million in Q3 2023 and bottomed at -$10.6 million in Q4 2022.
• Historically, Income towards Parent Company has averaged -$3.3 million across 5 years, with a median of -$2.9 million in 2024.
• The widest YoY moves for Income towards Parent Company: up 266.56% in 2023, down 635.56% in 2023.
• Over 5 years, Income towards Parent Company stood at -$10.6 million in 2022, then soared by 79.86% to -$2.1 million in 2023, then soared by 173.82% to $1.6 million in 2024, then dropped by 24.08% to $1.2 million in 2025, then tumbled by 125.98% to -$312000.0 in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$312000.0, -$2.2 million, and $1.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.